Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Structure-Activity Relationship Study of Dexrazoxane Analogues Reveals ICRF-193 as the Most Potent Bisdioxopiperazine against Anthracycline Toxicity to Cardiomyocytes Due to Its Strong Topoisomerase IIβ Interactions.
Jirkovská A, Karabanovich G, Kubeš J, Skalická V, Melnikova I, Korábečný J, Kučera T, Jirkovský E, Nováková L, Bavlovič Piskáčková H, Škoda J, Štěrba M, Austin CA, Šimůnek T, Roh J. Jirkovská A, et al. Among authors: skalicka v. J Med Chem. 2021 Apr 8;64(7):3997-4019. doi: 10.1021/acs.jmedchem.0c02157. Epub 2021 Mar 22. J Med Chem. 2021. PMID: 33750129
Investigation of Structure-Activity Relationships of Dexrazoxane Analogs Reveals Topoisomerase IIβ Interaction as a Prerequisite for Effective Protection against Anthracycline Cardiotoxicity.
Kollárová-Brázdová P, Jirkovská A, Karabanovich G, Pokorná Z, Bavlovič Piskáčková H, Jirkovský E, Kubeš J, Lenčová-Popelová O, Mazurová Y, Adamcová M, Skalická V, Štěrbová-Kovaříková P, Roh J, Šimůnek T, Štěrba M. Kollárová-Brázdová P, et al. Among authors: skalicka v. J Pharmacol Exp Ther. 2020 Jun;373(3):402-415. doi: 10.1124/jpet.119.264580. Epub 2020 Apr 6. J Pharmacol Exp Ther. 2020. PMID: 32253261
Clinically Translatable Prevention of Anthracycline Cardiotoxicity by Dexrazoxane Is Mediated by Topoisomerase II Beta and Not Metal Chelation.
Jirkovský E, Jirkovská A, Bavlovič-Piskáčková H, Skalická V, Pokorná Z, Karabanovich G, Kollárová-Brázdová P, Kubeš J, Lenčová-Popelová O, Mazurová Y, Adamcová M, Lyon AR, Roh J, Šimůnek T, Štěrbová-Kovaříková P, Štěrba M. Jirkovský E, et al. Among authors: skalicka v. Circ Heart Fail. 2021 Nov;14(11):e008209. doi: 10.1161/CIRCHEARTFAILURE.120.008209. Epub 2021 Sep 23. Circ Heart Fail. 2021. PMID: 34551586
Prospective and parallel assessments of cystic fibrosis newborn screening protocols in the Czech Republic: IRT/DNA/IRT versus IRT/PAP and IRT/PAP/DNA.
Krulišová V, Balaščaková M, Skalická V, Piskáčková T, Holubová A, Paděrová J, Křenková P, Dvořáková L, Zemková D, Kračmar P, Chovancová B, Vávrová V, Stambergová A, Votava F, Macek M Jr. Krulišová V, et al. Among authors: skalicka v. Eur J Pediatr. 2012 Aug;171(8):1223-9. doi: 10.1007/s00431-012-1747-z. Epub 2012 May 12. Eur J Pediatr. 2012. PMID: 22581207 Clinical Trial.
Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study.
Mlčoch T, Klimeš J, Fila L, Vávrová V, Skalická V, Turnovec M, Krulišová V, Jirčíková J, Zemková D, Dědečková KV, Bílková A, Frühaufová V, Homola L, Friedmannová Z, Drnek R, Dřevínek P, Doležal T, Macek M Jr. Mlčoch T, et al. Among authors: skalicka v. Eur J Health Econ. 2017 Jan;18(1):73-82. doi: 10.1007/s10198-015-0759-9. Epub 2016 Jan 7. Eur J Health Econ. 2017. PMID: 26743971
46 results